Diabetic neuropathy

American Family Physician

Volumn 54, Issue 8, 1996, Pages 2478-2484

  Lipnick, Jesse A ^a   Lee, Thomas H ^b  

^a Grant Medical Center ^*

^b Rehab Medical Associates PA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AMITRIPTYLINE PLUS PERPHENAZINE; CARBAMAZEPINE; DOXEPIN; PHENOXYBENZAMINE; PHENYTOIN;

ACHILLES REFLEX; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIFFERENTIAL DIAGNOSIS; ELECTROMYOGRAM; HUMAN; MORBIDITY; PATHOGENESIS; REVIEW; RISK ASSESSMENT; VIBRATION SENSE;

DIABETIC NEUROPATHIES; HUMANS; RISK FACTORS;

EID: 0029769780     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Diabetes: 1993 vital statistics. Alexandria, Va.: American Diabetes Association, 1993.
2. Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. Q J Med 1980;49:95-108.
3. Dyck PJ. Evaluative procedures to detect, characterize, and assess the severity of diabetic neuropathy. Diabet Med 1991;8:48-51.
4. Melton LJ. Clinical features of the diabetic neuropathies: epidemiology. In: Dyck PJ, et al, eds. Diabetic neuropathy. Philadelphia: Saunders, 1987:48-51.
5. Boulton AJ. Clinical presentation and management of diabetic neuropathy and foot ulceration. Diabet Med 1991;8:52-7.
6. Pirart J. Diabetes mellitus and its degenerative complications. A prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978;1:168-88.
7. Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. Diabetes 1988;37:476-81.
8. Greene DA, Sima AF, Pfeifer MA, Albers JW. Diabetic neuropathy. Annu Rev Med 1990;41:303-17.
9. 27th annual meeting of the European Association for the Study of Diabetes. Dublin, Ireland, 10-14 September 1991. Abstracts. Diabetologia 1991;34 Suppl 2:A1-220.
10. Woltman HW, Wilder RM. Diabetes mellitus: Pathological changes in the spinal cord and peripheral nerves. Arch Intern Med 1929;44:576-603.
11. Nukada H, Dyck PJ. Microsphere embolization of nerve capillaries and fiber degeneration. Am J Pathol 1984;115:275-87.
12. Jamal GA. Pathogenesis of diabetic neuropathy: the role of the n-6 essential fatty acids and their eicosanoid derivatives. Diabet Med 1990;7:574-9.
13. Sampson MJ, Wilson S, Karagiannis P, Edmonds M, Watkins PJ. Progression of diabetic autonomic neuropathy over a decade in insulin-dependent diabetics. Q J Med 1990;75:635-46.
14. Gabbay KH, Merola LO, Field RA. Sorbitol pathway: presence in nerve and cord with substrate accumulation in diabetes. Science 1966;151:209-10.
15. Greene DA, Lattimer SA, Sima AA. Are disturbances of sorbitol, phosphoinositide, and Na+-K+-ATPase regulation involved in pathogenesis of diabetic neuropathy? Diabetes 1988;37:688-93.
16. Greene DA, De Jesus PV Jr, Winegrad AI. Effects of insulin and dietary myoinositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes. J Clin Invest 1975;55:1326-36.
17. Greene DA, Lattimer SA. Sodium- and energy-dependent uptake of myo-inositol by rabbit peripheral nerve. Competitive inhibition by glucose and lack of an insulin effect. J Clin Invest 1982;70:1009-18.
18. Thomas PK, Eliasson SG. Diabetic neuropathy. In: Dyck PJ, et al, eds. Peripheral neuropathy. Philadelphia: W.B. Saunders Co., 1984:1773-1810.
19. Pirart J. Diabetic neuropathy: a metabolic or vascular disease? Diabetes 1965;14:1-9.
20. Archer AG, Watkins PJ, Thomas PK, Sharma AK, Payan J. The natural history of acute painful neuropathy in diabetes mellitus. J Neurol Neurosurg Psychiatry 1983;46:491-9.
21. Ewing DJ, Clarke BF. Diabetic autonomic neuropathy: a clinical viewpoint. In: Dyck PJ, et al, eds. Diabetic neuropathy. Philadelphia: Saunders, 1987:66-8.
22. Bradley LE, Linn JT. Assessment of diabetic sexual dysfunction and cystopathy. In: Dyck PJ, et al., eds. Diabetic neuropathy. Philadelphia: Saunders, 1987:146.
23. Asbury AK, Aldredge H, Hershberg R, Fisher CM. Oculomotor palsy in diabetes mellitus: a clinico-pathological study. Brain 1970;93:555-66.
24. Zorrilla E, Kozak GP. Ophthalmoplegia in diabetes mellitus. Ann Intern Med 1967;67:968-76.
25. Asbury AK. Focal and multi-focal neuropathies of diabetes. In: Dyck PJ, et al., eds. Diabetic Neuropathy. Philadelphia: Saunders, 1987:45-55.
26. Leedman PJ, Davis S, Harrison LC. Diabetic amyotrophy: reassessment of the clinical spectrum. Aust N Z J Med 1988;18:768-73.
27. Ellenberg M. Diabetic neuropathic cachexia. Diabetes 1974;23:418-23.
28. Frykberg RG. Podiatric problems in diabetes. Kozak GP, et al, eds. Management of diabetic foot problems: Joslin Clinic and New England Deaconess Hospital. Philadelphia: W.B. Saunders, 1984:45-67.
29. Brodsky JW. Outpatient diagnosis and care of the diabetic foot. Instr Course Lect 1993;42:121-39.
30. Gershkoff AM. Pain in neuropathy. In: Walsh NE, ed. Rehabilitation of chronic pain. Philadelphia: Hanley & Belfus, Inc. 1991:49-70.
31. Rasminsky M. Ephaptic transmission between single nerve fibres in the spinal nerve roots of dystrophic mice. J Physiol 1980;305:151-69.
32. Rull, JA, Quibrera R, Gonzalez-Millan H, Lozano Castaneda O. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial. Diabetologia 1969; 5:215-8.
33. Wilton TD. Tegretol in the treatment of diabetic neuropathy. S Afr Med J 1974;48:869-72.
34. Max MB, Culnane M, Schafer SC, Gracely RH, Walther DJ, Smoller B, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987;37:589-96.
35. Turkington RW. Depression masquerading as diabetic neuropathy. JAMA 1980;243:1147-50.
36. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86.
37. Judzewitsch RG, Jaspan JB, Polonsky KS, Weinberg CR, Halter JB, Halar E, et al. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. N Engl J Med 1983;308:119-25.
38. Greene DA, Bril V, Sima AAF. Aldose reductase inhibitors promote sural nerve fiber regeneration and repair in patients with diabetic neuropathy. Clin Res 1987;35(3):623.